2 completed, 2 withdrawn, 1 active not recruiting. 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Withdrawn 2, Active not recruiting 1, Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow VLA1553: new trials by email Literature Review of VLA1553 trials Research Report on VLA1553
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children VLA1553, Control - Chikungunya Virus Infection | Phase 3 | Withdrawn | Valneva Austria GmbH | 2026-02-06 | 2025-12-31 | |
| A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV) VLA1553 - Chikungunya Virus Infection | Phase 3 | Withdrawn | Valneva Austria GmbH | 2024-04-10 | 2024-12-02 | |
| Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553) VLA1553 - Chikungunya Virus Infection | Phase 3 | Active not recruiting | Valneva Austria GmbH | 363 | 2021-04-02 | 2026-07-09 |
| Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults VLA1553, Placebo - Chikungunya Virus Infection | Phase 3 | Completed | Valneva Austria GmbH | 4128 | 2020-09-17 | 2023-06-28 |
| Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers VLA1553 - Chikungunya | Phase 1 | Completed | Valneva Austria GmbH | 120 | 2018-03-05 | 2019-08-29 |
United States (3)
Nina Wressnigg (1)